Material Selection in Medical 3D Printing: Practical Guide

In every clinic where we start talking materials we meet the same scene: samples from three or four suppliers on the table, a comparison spreadsheet open on the screen, and justified confusion. On the datasheets they all look fine — high tensile strength, reasonable elongation, competitive price. The problem is that a datasheet describes how the material behaves as a laboratory test bar — not how the 2-millimetre-walled, curved, perforated AFO you are about to print will behave.

We will not recommend brands in this article. Instead we will lay out the selection logic we have settled on while working with clinics doing medical printing since our founding. Because the right question is not 'which material is best' but 'which material is right for this indication, this patient and this production line'.

Indication first, chemistry second

We think about selection along three axes. The first is skin contact: does the product touch skin, and for how long? A cranial helmet is in contact with skin 23 hours a day, for months — here a biocompatibility certificate is not negotiable. A prosthetic socket usually has a liner on its inner surface; contact is indirect, but sweat and heat are present. A check socket, meanwhile, retires within days. The three do not require the same certification level, and using premium material where it is not required only inflates cost.

The second axis is the mechanical scenario. 'Make it durable' means nothing in engineering terms; resistant to fracture, to flexing, or to cyclic load? An AFO's ankle region flexes with every step — hundreds of thousands of cycles. A rigid but brittle resin is a disaster there; you need a material with high fatigue strength, or a design-material combination that flexes in the right place. In insoles it is the opposite: controlled softness and resistance to permanent deformation come first.

The third axis is the one most often forgotten: post-processing. With SLA resins, the washing and UV-curing protocol directly determines the part's final mechanical and biocompatibility properties. An under-cured 'biocompatible' resin is no longer the material its certificate promises. If the clinic lacks the infrastructure to run that protocol identically every time, the material's on-paper superiority has no counterpart in the field.

The resin-versus-filament debate

In our view this debate is framed wrong; the two are not rivals but tools for different jobs. SLA resin is far ahead on surface quality and fine detail — for products like helmets, where both aesthetics and inner-surface smoothness matter, it is our default choice. FDM wins on large parts, on applications that need flexibility and on cost sensitivity; TPU insoles and some AFO designs live there.

An example from the field: one of our clinics planned to build its insole line entirely on rigid resin, because that was the printer they owned. Looking at the pressure-map data together, we saw that cases needing controlled collapse in the forefoot were the majority; we switched the line to TPU. Six months later they reported, based on their own records, that revision requests had dropped — a single clinic's observation, not a measured result we publish. Choosing the material for the case population rather than for the machine at hand — the whole matter is in that sentence.

Let us also touch on carbon-filled filaments, since they come up often. Yes, the stiffness-to-weight ratio is impressive. But carbon fill can weaken inter-layer adhesion, and strength varies sharply with print orientation. If you are going to use carbon in a load-bearing part, you need to have planned the print orientation around the part's force path. That knowledge is not on the datasheet; it comes with experience — or with the right platform.

The platform's role in all this

Here is how we built the material library in the Clonify Labs platform: every material ships with print profiles tested for specific indications — layer height, infill pattern, orientation and cure time included. When the clinician approves a design, the system suggests the profiles suited to the indication; the choice stays with the clinician, but the cost of trial and error has already been paid by the experience accumulated in the platform.

Still, let us say it plainly: no software removes the clinical responsibility of the material decision. What we do is firm up the ground that decision is made on. If you would like to talk through which combinations make sense for your own case mix, our materials team genuinely loves these conversations — you can reach us through the contact page.